e-learning
resources
Barcelona 2013
Sunday, 08.09.2013
Novel drugs and biomarkers in respiratory medicine
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Chemically modified mRNA as a novel treatment for cystic fibrosis
A. J. Mahiny, R. Handgretinger, D. Hartl, M. S. D. Kormann (Tuebingen, Germany)
Source:
Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine
Session:
Novel drugs and biomarkers in respiratory medicine
Session type:
Thematic Poster Session
Number:
747
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. J. Mahiny, R. Handgretinger, D. Hartl, M. S. D. Kormann (Tuebingen, Germany). Chemically modified mRNA as a novel treatment for cystic fibrosis. Eur Respir J 2013; 42: Suppl. 57, 747
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Cystic fibrosis and intestinal organoids
Late Breaking Abstract - Developing the pneumonia-optimized ratio for community-acquired pneumonia: an easy, inexpensive and accurate prognostic biomarker
Related content which might interest you:
Assessment of public awareness on chronic obstructive pulmonary disease in Slovenia
Source: International Congress 2014 – Management of COPD in primary care
Year: 2014
Development of a national patient charter for idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016
Health care system resource utilisation in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Interim analysis of the EXCITING-ILD registry
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
Quality of life measures in patients with idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view
Year: 2013
Health status & impact of living with idiopathic pulmonary fibrosis (IPF): UK & Ireland Delphi survey
Source: International Congress 2016 – IPF clinical
Year: 2016
Clinical, functional and microbiological characteristics of an adult brazilian cystic fibrosis population
Source: International Congress 2014 – Cystic fibrosis: clinical assessment and treatment
Year: 2014
Cystic fibrosis diagnosis in adulthood as a result of study of relatives within the newborn screening programme
Source: International Congress 2015 – Cystic fibrosis: assessment and treatment
Year: 2015
IPF Care, a support program for patients with idiopathic pulmonary fibrosis in the UK
Source: International Congress 2015 – Latest insights into chronic care
Year: 2015
Characterisation of a novel symptom of chronic obstructive pulmonary disease: Bendopnoea
Source: International Congress 2016 – Management of dyspnoea and exacerbations in chronic lung diseases
Year: 2016
Chronic lung disease in two patients with new integrin alfa3 gene mutations
Source: International Congress 2016 – Orphan diseases II
Year: 2016
Prevalence of occupational and environmental exposures in Australian patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2014 – Occupational asthma, abestosis and silicosis
Year: 2014
The burden of idiopathic pulmonary fibrosis reported by patients and carers in Ireland
Source: International Congress 2015 – IPF: clinical aspects
Year: 2015
The burden of chronic obstructive pulmonary disease (COPD) in Taiwan
Source: Annual Congress 2013 –Health economics of airway diseases
Year: 2013
Inspiration: An assistance program for idiopathic pulmonary fibrosis patients on pirfenidone
Source: International Congress 2014 – Respiratory symptoms in primary care populations
Year: 2014
Cognition in COPD patients
Source: International Congress 2016 – Best abstracts on innovative outcomes and novel interventions in respiratory physiotherapy
Year: 2016
Impact of pulmonary rehabilitation on quality of life in patients with silica exposure associated with progressive massive fibrosis
Source: International Congress 2014 – Occupational respiratory diseases: from drug-induced disease to COPD induced by the uranium industry
Year: 2014
Repeat pulmonary rehabilitation programmes: Are they beneficial in COPD?
Source: International Congress 2014 – Best posters in pulmonary rehabilitation 1
Year: 2014
Do GOLD stages of COPD severity really correspond to differences in health status?
Source: Eur Respir J 2003; 22: 444-449
Year: 2003
Predicting mortality in idiopathic pulmonary fibrosis. Which parameters should be used to determine eligibility for treatment? Analysis of a UK prospective cohort
Source: International Congress 2016 – The best is yet to come in terms of lung function
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept